-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
You May Also Like
Change Your Mood with a Quick Hit: Canopy Growth Launches whisl, First-Ever CBD Vape
Unity Rd., 100% Locally-Owned and Operated Dispensary Franchise, Strategically Positions Item 9 Labs Corp. for National Scale
Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis
-
A Look into Share CFDs and the Top 5 to Watch… Come Rise or Fall
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Contract trading has become increasingly popular on retail investment platforms. Derivative trades allow investors to quickly turn a profit without actually owning the investment. There are several explicit types of contract trading available —some of which include futures, options, and contracts for difference (CFDs). Because required account minimums and limits aren’t placed on the number of day trades that can be made under $25,000, CFDs are attractive to day traders and investors who like taking lucrative risks on moving investments. Many often find success…
